Core Laboratories (CLB) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
18 May, 2026Executive summary
Q1 2026 revenue was $121.8 million, down 12% sequentially and 1% year-over-year, reflecting lower international activity and ongoing geopolitical disruptions in the Middle East and Russia/Ukraine.
Net loss attributable to shareholders was $0.8 million, compared to net income of $4.9 million in Q4 2025 and a net loss of $0.2 million in Q1 2025.
Operating income declined to $1.9 million from $15.7 million last quarter and $4.4 million a year ago.
Operations were significantly impacted by geopolitical instability, severe weather in North America and Europe, and disruptions to hydrocarbon transportation and trading routes.
The company celebrated its 90th anniversary, emphasizing resilience and a commitment to long-term value creation.
Financial highlights
Service revenue was $94.3 million (down 1% YoY, down 12% sequentially); product sales were $27.5 million (down 3% YoY, down 12% sequentially).
Net income ex items was $2.7 million, down 72% sequentially and 59% year-over-year; GAAP net loss was $800,000.
EBIT ex items was $6.6 million (5% margin), down from $15.7 million last quarter; GAAP EBIT was $1.9 million.
EPS ex items was $0.06, compared to $0.21 last quarter and $0.14 a year ago; GAAP loss per share was $0.02.
Free cash flow was $0.5 million after $3.5 million in CapEx; $1.4 million in CapEx for UK facility rebuild excluded from FCF.
Outlook and guidance
Q2 2026 revenue projected at $123–$131 million, with operating income of $6.4–$10.2 million and EPS of $0.06–$0.12.
Reservoir Description Q2 revenue expected at $77.5–$82.5 million; Production Enhancement at $45.5–$48.5 million.
Modest sequential operational improvement expected, but Middle East volatility creates uncertainty in recovery timing.
Multi-year cycle of international offshore exploration and development anticipated to support future demand.
U.S. onshore activity is expected to be more sensitive to oil price changes, while large-scale international projects are seen as more resilient.
Latest events from Core Laboratories
- 2025 meeting covers director elections, auditor ratification, and performance-based executive pay.CLB
Proxy filing18 May 2026 - Votes will address director elections, auditor ratification, and executive compensation approval.CLB
Proxy filing18 May 2026 - Sequential revenue and margin growth, 21% net income rise, and share buybacks marked Q3 2025.CLB
Q3 202518 May 2026 - Proxy covers director elections, auditor ratification, and executive pay, with strong ESG focus.CLB
Proxy filing18 May 2026 - Votes on director re-election, auditor ratification, and executive pay set for May 2026.CLB
Proxy filing18 May 2026 - Q4 revenue up 7% year-over-year; Q1 2026 guidance: $124–$130M revenue, $0.11–$0.15 EPS.CLB
Q4 20255 Feb 2026 - Q2 2024 delivered higher margins, strong cash flow, and international growth despite U.S. softness.CLB
Q2 20243 Feb 2026 - Q3 2024 delivered 7% revenue growth, margin gains, and record-low leverage on strong international demand.CLB
Q3 202418 Jan 2026 - Full-year growth in revenue and EPS, strong cash flow, and improved leverage amid global risks.CLB
Q4 20249 Jan 2026